Dual Enkephalinase Inhibitors (DENKIs) are involved in the regulation of nociception via opioid receptors. The novel compound STR-324 belongs to the DENKI pharmacological class. This first-in-human study evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324 in healthy male participants.
First-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management.
CHDR
Moss LM, Berends CL, van Brummelen EMJ, Kamerling IMC, Klaassen ES, Bergmann K, Ville V, Juarez-Perez V, Benichou AC, Groeneveld GJ
